GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cytek Biosciences Inc (NAS:CTKB) » Definitions » Price-to-Owner-Earnings

Cytek Biosciences (Cytek Biosciences) Price-to-Owner-Earnings : (As of Apr. 29, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cytek Biosciences Price-to-Owner-Earnings?

As of today (2024-04-29), Cytek Biosciences's share price is $5.76. Cytek Biosciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Cytek Biosciences's Price-to-Owner-Earnings or its related term are showing as below:


CTKB's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 32.985
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-29), Cytek Biosciences's share price is $5.76. Cytek Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.09. Therefore, Cytek Biosciences's PE Ratio for today is At Loss.

As of today (2024-04-29), Cytek Biosciences's share price is $5.76. Cytek Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.09. Therefore, Cytek Biosciences's PE Ratio without NRI for today is At Loss.

During the past 5 years, Cytek Biosciences's highest PE Ratio without NRI was 3703.33. The lowest was 0.00. And the median was 593.75.


Cytek Biosciences Price-to-Owner-Earnings Historical Data

The historical data trend for Cytek Biosciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytek Biosciences Price-to-Owner-Earnings Chart

Cytek Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - - -

Cytek Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cytek Biosciences's Price-to-Owner-Earnings

For the Medical Devices subindustry, Cytek Biosciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytek Biosciences's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Cytek Biosciences's Price-to-Owner-Earnings falls into.



Cytek Biosciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Cytek Biosciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=5.76/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cytek Biosciences  (NAS:CTKB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Cytek Biosciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Cytek Biosciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytek Biosciences (Cytek Biosciences) Business Description

Traded in Other Exchanges
Address
47215 Lakeview Boulevard, Fremont, CA, USA, 94538
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance.
Executives
Patrick Jeanmonod officer: Chief Financial Officer C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Ming Yan director, officer: Chief Technology Officer C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Wenbin Jiang director, officer: President and CEO C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Philippe Busque officer: SVP, Global Sales and Services 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Jack Ball director C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Paul Christopher Williams officer: Chief Operating Officer C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Don M Hardison director
Deborah J Neff director C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BLVD., FREMONT CA 94538
Jonathan Todd Garland officer: Chief Commercial Officer C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Ra Capital Healthcare Fund Lp director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Vera Imper director C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Theresa Cameron director C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116
Feng Deng director SUITE 1701, 17/F HUTCHISON HOUSE, 10 HARCOURT ROAD, CENTRAL, HONG KONG K3 00000
Ra Capital Nexus Fund Ii, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116